KCA
Search
- Page Path
- HOME > Search
Review Article
- Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
- Changhoon Yoo, Chung Ryul Oh, Seung-Tae Kim, Woo Kyun Bae, Hye-Jin Choi, Do-Youn Oh, Myung-Ah Lee, Baek-Yeol Ryoo
- Cancer Res Treat. 2021;53(2):291-300. Published online December 29, 2020
- DOI: https://doi.org/10.4143/crt.2020.1233
-
Abstract
PDF
PubReader
ePub - Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients. We here provide a consensus review of the diagnosis, staging and systemic treatment of Korean GEP-NET patients. Systemic therapy options and the current Korean expert consensus on these treatments, including somatostatin analogs, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide treatments, and cytotoxic chemotherapies are addressed.
-
Citations
Citations to this article as recorded by
- Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
Yeokyeong Shin, Bo Hyun Moon, Baek-Yeol Ryoo, Heung-Moon Chang, Kyu-pyo Kim, Yong Sang Hong, Tae Won Kim, Jin-Sook Ryu, Yong-il Kim, Changhoon Yoo
Targeted Oncology.2024; 19(1): 41. CrossRef - Effectiveness and Safety of Retreatment with177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States
Ebrahim S. Delpassand, Soheil M. Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, Jeetvan Patel
Journal of Nuclear Medicine.2024; 65(5): 746. CrossRef - Advances in hydrogel materials applied to pancreatic-related diseases
Yuan Zhou, Maoen Pan, Ronggui Lin, Heguang Huang
Journal of Pancreatology.2024; 7(3): 222. CrossRef - Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy
Eonwoo Shin, Yong-il Kim, Changhoon Yoo, Yeokyeong Shin, Baek-Yeol Ryoo, Dong Yun Lee, Jin-Sook Ryu
European Radiology.2024;[Epub] CrossRef - Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors
Boris G. Naraev, Josh Mailman, Thorvardur R. Halfdanarson, Heloisa P. Soares, Erik S. Mittra, Julie Hallet
Expert Review of Anticancer Therapy.2023; 23(6): 601. CrossRef - KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef - Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
Eun-Joo Park, Hyo-Jung Park, Kyung-Won Kim, Chong-Hyun Suh, Changhoon Yoo, Young-Kwang Chae, Sree Harsha Tirumani, Nikhil H. Ramaiya
Cancers.2022; 14(3): 794. CrossRef - Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Krzysztof Kaliszewski, Maksymilian Ludwig, Maria Greniuk, Agnieszka Mikuła, Karol Zagórski, Jerzy Rudnicki
Cancers.2022; 14(8): 2028. CrossRef - Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
H. Jeong, J. Shin, J.H. Jeong, K.-p. Kim, S.-M. Hong, Y.-i. Kim, J.-S. Ryu, B.-Y. Ryoo, C. Yoo
ESMO Open.2021; 6(3): 100119. CrossRef
- Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
- 10,246 View
- 373 Download
- 10 Web of Science
- 9 Crossref
Original Article
- Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
- Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang
- Cancer Res Treat. 2017;49(2):350-357. Published online July 19, 2016
- DOI: https://doi.org/10.4143/crt.2016.067
-
Abstract
PDFPubReaderePub
- Purpose
The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients.
Materials and Methods
Fifty-seven Korean patientswith advanced GISTwho experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off).
Results
None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for ≥ 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31).
Conclusion
This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials. -
Citations
Citations to this article as recorded by- English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
International Journal of Clinical Oncology.2024; 29(6): 647. CrossRef - A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
British Journal of Cancer.2023; 129(2): 275. CrossRef - Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
Frontiers in Oncology.2023;[Epub] CrossRef - Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
Cancers.2023; 15(16): 4081. CrossRef - Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review
Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen
Critical Reviews in Oncology/Hematology.2022; 172: 103650. CrossRef - Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson
Cancers.2022; 14(7): 1832. CrossRef - Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors
Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
International Journal of Clinical Oncology.2022; 27(7): 1164. CrossRef - The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee, Raga Sruthi Dwarampudi, Sheena Mathew, Sumahitha Bichenapally, Lubna Mohammed
Cureus.2022;[Epub] CrossRef - CT Image Examination Based on Virtual Reality Analysis in Clinical Diagnosis of Gastrointestinal Stromal Tumors
Zhiying Wang, Qiaoyan Qu, Ke Cai, Ting Xu, Zhihan Lv
Journal of Healthcare Engineering.2021; 2021: 1. CrossRef - The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska
International Journal of Molecular Sciences.2021; 22(21): 12089. CrossRef - Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors
Seketoulie Keretsu, Suparna Ghosh, Seung Joo Cho
International Journal of Molecular Sciences.2020; 21(21): 8232. CrossRef - Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study
Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh
Oncology Letters.2020; 20(3): 2131. CrossRef - Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers
Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li, Houjie Liang
Advances in Therapy.2019; 36(8): 1986. CrossRef - Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
The Oncologist.2019; 24(11): e1212. CrossRef - Growing Role of Regorafenib in the Treatment of Patients with Sarcoma
Mark Agulnik, Steven Attia
Targeted Oncology.2018; 13(4): 417. CrossRef - Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Ne
Scientific Reports.2017;[Epub] CrossRef - Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Bin Zhao, Hong Zhao
Oncotarget.2017; 8(55): 93813. CrossRef
- English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
- 10,274 View
- 371 Download
- 22 Web of Science
- 17 Crossref
Special Article
- Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
- Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
- Cancer Res Treat. 2016;48(4):1155-1166. Published online June 24, 2016
- DOI: https://doi.org/10.4143/crt.2016.187
-
Abstract
PDFPubReaderePub
- Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.
-
Citations
Citations to this article as recorded by- Clinical importance of tumor rupture in gastrointestinal stromal tumor
Toshirou Nishida, Naoto Gotouda, Tsuyoshi Takahashi, Hui Cao
Journal of Digestive Diseases.2024; 25(9-10): 542. CrossRef - Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis
Chunhui Shou, Zhou Chen, Zhijian Li, Weili Yang, Qing Zhang, Hao Bai, Jiren Yu
Scandinavian Journal of Gastroenterology.2024; 59(2): 239. CrossRef - Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors
Toshihiko Doi, Noboru Yamamoto, Shuichi Ohkubo
Future Oncology.2024; 20(9): 507. CrossRef - Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China
Zhengting He, Chen Du, Bingqian Cheng, Jiancong Feng, Nanjun Wang, Yan Ma, Longsong Li, Bo Zhang, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
Surgical Endoscopy.2024; 38(3): 1398. CrossRef - Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors
Jing-wen Zhang, Chang-qing Guo, Shan-shan Zhu, Ghulam Nabi, Nan Dai, Xiao-yu Wan, Ping Liu, Fang-bin Zhang, Yang Fu, Xin-gung Cao
Digestive Diseases and Sciences.2024; 69(5): 1755. CrossRef - Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images
Mingyan Cai, Baohui Song, Yinhui Deng, Pingting Gao, Shilun Cai, Ayimukedisi Yalikong, Enpan Xu, Yunshi Zhong, Jinhua Yu, Pinghong Zhou
Gastrointestinal Endoscopy.2024; 99(4): 537. CrossRef - English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
International Journal of Clinical Oncology.2024; 29(6): 647. CrossRef - Efficacy and Safety of Endoscopic Resection for Gastric Gastrointestinal Stromal Tumors Originating from the Muscularis Propria
Ji Li, Dong Xu, Wei-Feng Huang, Shao-Kun Hong, Jin-Yan Zhang
Digestive Diseases and Sciences.2024; 69(6): 2184. CrossRef - Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study
Enpan Xu, Qiang Shi, Zhipeng Qi, Bing Li, Huihui Sun, Zhong Ren, Shilun Cai, Dongli He, Zhengtao Lv, Zhanghan Chen, Liang Zhong, Leiming Xu, Xiaobo Li, Shuchang Xu, Pinghong Zhou, Yunshi Zhong
Surgical Endoscopy.2024; 38(6): 3353. CrossRef - Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative)
Johnn Henry Herrera Kok, Luigi Marano, Jan Willem van den Berg, Preethi Shetty, Yogesh Vashist, Laura Lorenzon, Beate Rau, Richard van Hillegersberg, Giovanni de Manzoni, Andrea Spallanzani, Won Jun Seo, Hiromi Nagata, Clarisse Eveno, Stefan Mönig, Karen
European Journal of Surgical Oncology.2024; 50(7): 108387. CrossRef - Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study
Zhixia Dong, Xiangyun Zhao, Hangbin Zheng, HanYao Zheng, Dafan Chen, Jia Cao, Zili Xiao, Yunwei Sun, Qian Zhuang, Shan Wu, Jie Xia, Min Ning, Binjie Qin, Hui Zhou, Jinsong Bao, Xinjian Wan
eClinicalMedicine.2024; 73: 102656. CrossRef - Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Changhoon Yoo, Sung-Joo Kim, Yoon-Koo Kang
Clinical Cancer Research.2024; 30(13): 2743. CrossRef - Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST)
Shanshan Zhu, Changqing Guo, Jingwen Zhang, Nan Dai, Saif Ullah, Ping Liu, Yang Fu, Ge Zhang, Fangbin Zhang, Shengang Zhang, Xinguang Cao
European Journal of Surgical Oncology.2024; 50(9): 108527. CrossRef - Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Sh
BJC Reports.2024;[Epub] CrossRef - Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)
Sejin Kim, Hyung-Don Kim, Eo Jin Kim, Min-Hee Ryu, Yoon-Koo Kang
BMC Cancer.2024;[Epub] CrossRef - Unraveling Gastric and Small Intestine Gastrointestinal Stromal Tumors: A Review of Our Current Knowledge
Panagiotis Eskitzis, Vasiliki Michou, Rodoula Theoti, Antonia Antoniou, Drosos Tsavlis, Doxakis Anestakis
Gastrointestinal Disorders.2024; 6(4): 842. CrossRef - Mean platelet volume/platelet count ratio can predict the recurrence-free survival rate of patients after complete resection of gastrointestinal stromal tumors
Xinlian Du, Xinxin Zang, Hanbo Zhang, Lijia Liu, Ying Xu, Xuedong Li, Ruishu Mou, Haitao Xu, Jiuxin Zhu, Rui Xie
Frontiers in Oncology.2024;[Epub] CrossRef - Genotypical analysis of gastrointestinal stromal tumors using next-generation sequencing
Trupti V. Deshpande, Pranav Dorwal, Akshay A Anikhindi, Nishant Tiwari, Dharmendar Jain, Simmi Mehra, Ashok Vaid, Vimarsh Raina
Indian Journal of Cancer.2024; 61(3): 477. CrossRef - Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
Journal of Gastrointestinal Cancer.2023; 54(1): 316. CrossRef - Splenic capsulitis associated with gastric GIST
Soumya Hariswamy, Sam Alhayo, Yasser Farooque
ANZ Journal of Surgery.2023; 93(4): 1104. CrossRef - Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications
Michela Campora, Michele Paudice, Alessandro Gambella, Danila Comandini, Paola Parente, Marta Sbaraglia, Angelo Paolo Dei Tos, Federica Grillo, Luca Mastracci
Virchows Archiv.2023; 482(3): 589. CrossRef - Pure endoscopic resection versus laparoscopic assisted procedure for upper gastrointestinal stromal tumors: Perspective from a surgical endoscopist
Hon Chi Yip, Jun Liang Teh, Anthony Y. B. Teoh, Philip Chiu
Digestive Endoscopy.2023; 35(2): 184. CrossRef - Gastrointestinal stromal tumor of jejunum misdiagnosed as uterine leiomyoma: A case report
Min Yu, Miaomiao Sun, Shanwei Guo, Fangfang Nan
Asian Journal of Surgery.2023; 46(3): 1457. CrossRef - A Rare Gastric Subepithelial Lesion Removed through Submucosal Tunneling Endoscopic Resection: Case Report and Literature Review
Mu-Ming Chien, Yun-Ho Lin, Chun-Chao Chang, Hsi-Yuan Chien
Life.2023; 13(1): 179. CrossRef - Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach
Moon Kyung Joo, Jong-Jae Park, Yeon Ho Lee, Beom Jae Lee, Seong Min Kim, Won Shik Kim, Ah Young Yoo, Hoon Jai Chun, Sang Woo Lee
Gut and Liver.2023; 17(2): 217. CrossRef - Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
Yoichi Naito, Toshirou Nishida, Toshihiko Doi
Gastric Cancer.2023; 26(3): 339. CrossRef - Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions
Yoon-Koo Kang, Hyung-Don Kim, Hyun Jin Kim, Young Soo Park, Mo-Youl Beck, Min-Hee Ryu
Gastric Cancer.2023; 26(4): 604. CrossRef - Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study
Muhan Ni, Dehua Tang, Wei Ren, Rui Meng, Jinping Yang, Peng Yan, Xiwei Ding, Guifang Xu, Ying Lv, Min Chen, Hua Yang, Lei Wang
Gastric Cancer.2023; 26(4): 590. CrossRef - Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China
Jia-Xin Xu, Tian-Yin Chen, Yan-Bo Liu, Xiao-Yue Xu, Wei-Feng Chen, Quan-Lin Li, Jian-Wei Hu, Wen-Zheng Qin, Ming-Yan Cai, Yi-Qun Zhang, Ping-Hong Zhou
Surgical Endoscopy.2023; 37(8): 5883. CrossRef - Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis
Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang
Cancer Medicine.2023; 12(11): 12187. CrossRef - A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
British Journal of Cancer.2023; 129(2): 275. CrossRef - Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China
Chen Du, Zhengting He, Longsong Li, Bo Ning, Bo Zhang, Yaqi Zhai, Yan Ma, Ke Han, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102152. CrossRef - Gastrointestinal Stromal Tumor of Small Intestine
Hyo Yeop Song, Geom Seog Seo, Hoon Gil Jo
The Korean Journal of Gastroenterology.2023; 81(6): 276. CrossRef - Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa
Gastric Cancer.2023; 26(5): 775. CrossRef - Non-exposed endoscopic wall-inversion surgery with one-step nucleic acid amplification for early gastrointestinal tumors: Personal experience and literature review
Francesco Crafa, Serafino Vanella, Aristide Morante, Onofrio A Catalano, Kelsey L Pomykala, Mario Baiamonte, Maria Godas, Alexandra Antunes, Joaquim Costa Pereira, Valentina Giaccaglia
World Journal of Gastroenterology.2023; 29(24): 3883. CrossRef - Transgastric endoscopic ultrasound‐guided fine needle biopsy for diagnosing gastrointestinal stromal tumor of the jejunum
Yuichi Takano, Fumitaka Niiya, Masatsugu Nagahama
Digestive Endoscopy.2023;[Epub] CrossRef - Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor
Yating Wang, Genji Bai, Hui Zhang, Wei Chen
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef - Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors
Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Hung-Chi Chang, Chew-Teng Kor, Szu-Chia Wu, Kuo-Hua Lin
World Journal of Gastrointestinal Surgery.2023; 15(8): 1629. CrossRef - Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors
Ximei Ren, Muhan Ni, Tingting Zhu, Jinping Yang, Jinyan Liu, Shahzeb Hassan, Xiaoping Zou, Guifang Xu, Lei Wang
Digestive Diseases.2023; 41(2): 187. CrossRef - A giant gastric stromal tumor with dizziness as the main complaint: A case report and literature review
Dongdong Zhang, Shuk Ying WONG, Jixiang Wu, Limin Guo
International Journal of Surgery Case Reports.2023; 110: 108747. CrossRef - Survival outcome of local versus radical resection for jejunoileal gastrointestinal stromal tumors: a propensity score-matched population-based analysis
Shangcheng Yan, Wei Peng, Ming Cheng, Jingyu Zhang, Tianhua Liu, Mengchao Sheng, Rui Ren, Qiang Chen, Wei Gong, Yongyou Wu
International Journal of Colorectal Disease.2023;[Epub] CrossRef - CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series
Li-Jun Chen, Yue-Dong Han, Ming Zhang
BMC Medical Imaging.2023;[Epub] CrossRef - Rapidly Growing, High-Risk Gastrointestinal Stromal Tumor of the Stomach: A Case Report
Sung Jin Lim, Han Mo Yoo, Seung-Woo Lee, Hae Joung Sul, Dong Soo Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2023; 23(4): 306. CrossRef - Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study
Jia-Zheng Liu, Zhong-Wen Jia, Ling-Ling Sun
World Journal of Radiology.2023; 15(12): 350. CrossRef - Clinical outcomes of endoscopic resection for the treatment of gastric gastrointestinal stromal tumors originating from the muscularis propria: a 7-year experience from a large tertiary center in China
Chen Du, Ningli Chai, Enqiang Linghu, Huikai Li, Yaqi Zhai, Longsong Li, Xiaowei Tang, Hongbin Wang, Ping Tang
Surgical Endoscopy.2022; 36(2): 1544. CrossRef - Radiomics Nomogram Based on Contrast-enhanced CT to Predict the Malignant Potential of Gastrointestinal Stromal Tumor: A Two-center Study
Yancheng Song, Jie Li, Hexiang Wang, Bo Liu, Chentong Yuan, Hao Liu, Ziwen Zheng, Fanyi Min, Yu Li
Academic Radiology.2022; 29(6): 806. CrossRef - Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors
Keiko Maekawa, Masahiro Yamamura, Atsushi Matsuki, Takashi Ishikawa, Toshihiro Hirai, Yoshiyuki Yamaguchi, Yoshiro Saito, Tatsuo Kanda
Drug Metabolism and Pharmacokinetics.2022; 43: 100441. CrossRef - Clinical Course of Small Subepithelial Tumors of the Small Bowel Detected on CT
Seohyun Kim, Seung Joon Choi, Su Joa Ahn, So Hyun Park, Young Sup Shim, Jeong Ho Kim
Journal of the Korean Society of Radiology.2022; 83(3): 608. CrossRef - Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China
Deqiong Wang, Qiang Ding, Li Cao, Xinxia Feng, Zerui Zhang, Panpan Lu, Xiaoyu Ji, Lili Li, Dean Tian, Mei Liu
Scandinavian Journal of Gastroenterology.2022; 57(8): 996. CrossRef - The Diagnosis of Small Gastrointestinal Subepithelial Lesions by Endoscopic Ultrasound-Guided Fine Needle Aspiration and Biopsy
Masanari Sekine, Takeharu Asano, Hirosato Mashima
Diagnostics.2022; 12(4): 810. CrossRef - A Huge Malignant Gastric Gastrointestinal Stromal Tumor in a Young Patient
Yun Jin Jeong, Hyun Seung Hwang, Yong Eun Park, Kyung Han Nam, Sung Jin Oh
The Korean Journal of Gastroenterology.2022; 79(4): 177. CrossRef - Advancements in the Diagnosis of Gastric Subepithelial Tumors
Osamu Goto, Mitsuru Kaise, Katsuhiko Iwakiri
Gut and Liver.2022; 16(3): 321. CrossRef - Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Cancer Research and Treatment.2022; 54(4): 1167. CrossRef - The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection
Hui Qu, ZhaoHui Xu, YanYing Ren, ZeZhong Gong, Ri Hyok Ju, Fan Zhang, Shuai Shao, XiaoLiang Chen, Xin Chen
Medicine.2022; 101(25): e29487. CrossRef - Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
International Journal of Cancer.2022; 151(10): 1770. CrossRef - Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study
Zhou Zhao, Xiao-Nan Yin, Jian Wang, Xin Chen, Zhao-Lun Cai, Bo Zhang
World Journal of Gastroenterology.2022; 28(27): 3476. CrossRef - Therapeutic Effects of 4 Surgical Approaches for Small Gastrointestinal Stromal Tumors: A Network Meta-analysis
Zhiyuan Yu, Huaiyu Tu, Chen Liang, Shuzhong Qiu, Xiaoyu Dong, Yonghui Zhang, Chao Ma, Peiyu Li
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022;[Epub] CrossRef - Necessity of Individualized Approach for Gastric Subepithelial Tumor Considering Pathologic Discrepancy and Surgical Difficulty Depending on the Gastric Location
Sung Gon Kim, Bang Wool Eom, Hongman Yoon, Myeong-Cheorl Kook, Young-Woo Kim, Keun Won Ryu
Journal of Clinical Medicine.2022; 11(16): 4733. CrossRef - Laparoscopic versus open resection for the treatment of gastric GIST: a retrospective 10-year single-center experience
Andrea LOCATELLI, Daniele CARZANIGA, Pierluigi CARZANIGA, Andrea COSTANZI
Minerva Surgery.2022;[Epub] CrossRef - Case report: 10-year survival of a patient with a primary hepatic gastrointestinal stromal tumor
Jie Lian, Meiyan Feng, Shumei Zhang, Haibo Lu
Frontiers in Oncology.2022;[Epub] CrossRef - Clinical outcomes of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor
Hiroyuki Hanayama, Masanori Katagata, Takahiro Sato, Hiroshi Nakano, Takuro Matsumoto, Takeshi Tada, Yohei Watanabe, Suguru Hayase, Hirokazu Okayama, Tomoyuki Momma, Tsunetaka Kato, Minami Hashimoto, Jun Nakamura, Takuto Hikichi, Zenichiro Saze, Koji Kono
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE.2022; 68(3): 169. CrossRef - Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Yuichi Ichinose, Yi-Hsin Yang, Hui-Jen Tsai, Ru-Yu Huang, Takahiro Higashi, Toshirou Nishida, Li-Tzong Chen
Scientific Reports.2022;[Epub] CrossRef - Gastrointestinal stromal tumor of the small intestine of high malignant potential
Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
PONS - medicinski casopis.2022; 19(1): 33. CrossRef - Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine
Bozhi Hu, Chao Wang, Kewei Jiang, Zhanlong Shen, Xiaodong Yang, Mujun Yin, Bin Liang, Qiwei Xie, Yingjiang Ye, Zhidong Gao
BMC Gastroenterology.2021;[Epub] CrossRef - Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population‐based study
Lu Xu, Yanpeng Ma, Shengfeng Wang, Jingnan Feng, Lili Liu, Jinxi Wang, Guozhen Liu, Dianrong Xiu, Wei Fu, Siyan Zhan, Tao Sun, Pei Gao
Cancer Medicine.2021; 10(2): 737. CrossRef - Malignant solitary fibrous tumor of the greater omentum: A case report and review of literature
Yu-Chen Guo, Li-Yu Yao, Zhi-Sen Tian, Bing Shi, Ying Liu, Yuan-Yi Wang
World Journal of Clinical Cases.2021; 9(2): 445. CrossRef - A Case of Liver Metastasis from Small Intestinal Gastrointestinal Stromal Tumor 25 Years after Surgery including Autopsy Findings
Yuichi Takano, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Takahiro Kobayashi, Fumitaka Niiya, Eiichi Yamamura, Naotaka Maruoka, Kuniyo Gomi, Yuichiro Kuroki, Yorimasa Yamamoto, Tomoko Norose, Nobuyuki Ohike, Masatsugu Nagahama, Marcel Cerqueira Cesar Ma
Case Reports in Gastrointestinal Medicine.2021; 2021: 1. CrossRef - Gastrointestinal stromal tumours
Jean-Yves Blay, Yoon-Koo Kang, Toshiroo Nishida, Margaret von Mehren
Nature Reviews Disease Primers.2021;[Epub] CrossRef - A modified endoscopic full thickness resection for gastric subepithelial tumors from muscularis propria layer: Novel method
Jung Min Lee, In Kyung Yoo, Sung Pyo Hong, Joo Young Cho, Young Kwan Cho
Journal of Gastroenterology and Hepatology.2021; 36(9): 2558. CrossRef - Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
Toshirou Nishida, Shigetaka Yoshinaga, Tsuyoshi Takahashi, Yoichi Naito
Cancers.2021; 13(13): 3158. CrossRef - Diagnosis of gastric submucosal tumors and estimation of malignant risk of GIST by endoscopic ultrasound. Comparison between B mode and contrast-harmonic mode
Christine Lefort, Vikas Gupta, Andrea Lisotti, Laurent Palazzo, Pietro Fusaroli, Bertrand Pujol, Rodica Gincul, Fabien Fumex, Maxime Palazzo, Bertrand Napoléon
Digestive and Liver Disease.2021; 53(11): 1486. CrossRef - Gastrointestinal Stromal Tumors—A Mini Review
Gina Gheorghe, Nicolae Bacalbasa, Gabriela Ceobanu, Madalina Ilie, Valentin Enache, Gabriel Constantinescu, Simona Bungau, Camelia Cristina Diaconu
Journal of Personalized Medicine.2021; 11(8): 694. CrossRef - Controversies in EUS: Do we need miniprobes?
Hans Seifert, Pietro Fusaroli, PaoloGiorgio Arcidiacono, Barbara Braden, Felix Herth, Michael Hocke, Alberto Larghi, Bertrand Napoleon, Mihai Rimbas, BogdanSilvio Ungureanu, Adrian Sãftoiu, AnandV Sahai, ChristophF Dietrich
Endoscopic Ultrasound.2021; 10(4): 246. CrossRef - Convolutional neural network‐based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images
Chang Kyo Oh, Taewan Kim, Yu Kyung Cho, Dae Young Cheung, Bo‐In Lee, Young‐Seok Cho, Jin Il Kim, Myung‐Gyu Choi, Han Hee Lee, Seungchul Lee
Journal of Gastroenterology and Hepatology.2021; 36(12): 3387. CrossRef - The Value of Endoscopic Ultrasonography in the Endoscopic Resection of Gastrointestinal Stromal Tumors
Jian-Wei Mi, Jia-Qi Wang, Jie Liu, Li-Xian Zhang, Hong-Wei Du, Dong-Qiang Zhao
International Journal of General Medicine.2021; Volume 14: 5149. CrossRef - Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor
Jia Liu, Yuyong Tan, Deliang Liu, Chenjie Li, Meixian Le, Hejun Zhou
Journal of International Medical Research.2021;[Epub] CrossRef - Endoscopic Resection of Gastrointestinal Stromal Tumor: Is It Safe?
Moon Kyung Joo
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 180. CrossRef - Endoscopic Resection for Gastric Subepithelial Tumor with Backup Laparoscopic Surgery: Description of a Single-Center Experience
Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Joseph Lin, Kuo-Hua Lin
Journal of Clinical Medicine.2021; 10(19): 4423. CrossRef - Successful Endoscopic Resection of a Rectal Gastrointestinal Stromal Tumor Larger Than 5 cm
Seong Jung Kim, Yun Jung, Ran Hong, Jun Lee
The Korean Journal of Gastroenterology.2021; 78(4): 235. CrossRef - A Nomogram for Predicting Laparoscopic and Endoscopic Cooperative Surgery during the Endoscopic Resection of Subepithelial Tumors of the Upper Gastrointestinal Tract
Shun-Wen Hsiao, Mei-Wen Chen, Chia-Wei Yang, Kuo-Hua Lin, Yang-Yuan Chen, Chew-Teng Kor, Siou-Ping Huang, Hsu-Heng Yen
Diagnostics.2021; 11(11): 2160. CrossRef - Building Radiomics Models Based on Triple-Phase CT Images Combining Clinical Features for Discriminating the Risk Rating in Gastrointestinal Stromal Tumors
Meihua Shao, Zhongfeng Niu, Linyang He, Zhaoxing Fang, Jie He, Zongyu Xie, Guohua Cheng, Jian Wang
Frontiers in Oncology.2021;[Epub] CrossRef - Gastrointestinal stromal tumor of the rectum resected by transanal total mesorectal excision after neoadjuvant imatinib treatment: A case report
Takuya Yano, Masahiro Nakahara, Hiroshi Okuda, Toshihiko Nishidate, Ichiro Takemasa, Masahiko Fujimori, Hirofumi Nakatsuka, Hironobu Amano, Hideki Ohdan, Toshio Noriyuki
Asian Journal of Endoscopic Surgery.2020; 13(4): 574. CrossRef - Wedge gastrectomy: Robot-assisted with a hand-sewn repair versus a laparoscopic linear stapler technique for gastric subepithelial tumors
Chairat Supsamutchai, Thitipong Setthalikhit, Chumpon Wilasrusmee, Pornraksa Ovartchaiyapong, Jakrapan Jirasiritham, Pattawia Choikrua, Pitichote Hiranyatheb
Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(1): 17. CrossRef - Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
Heejung Chae, Min-Hee Ryu, Jungeun Ma, Moyeol Beck, Yoon-Koo Kang
Investigational New Drugs.2020; 38(2): 493. CrossRef - Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors
Jian Wang, Yuan Yin, Chaoyong Shen, Xiaonan Yin, Zhaolun Cai, Lin Pu, Wei Fu, Yaxuan Wang, Bo Zhang
Medicine.2020; 99(9): e19275. CrossRef - Multiple Intra-abdominal Leiomyosarcoma in a Single Patient
Rajshekhar C. Jaka, N. Chandra Mouli, T. Ravi Kumar, Akshay V. Gokak
Indian Journal of Surgical Oncology.2020; 11(S1): 63. CrossRef - Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors
Caiyue Ren, Shengping Wang, Shengjian Zhang
Cancer Imaging.2020;[Epub] CrossRef Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research
Fangxing Peng, Yao Liu
Cancer Management and Research.2020; Volume 12: 3877. CrossRef- Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: A preliminary meta‐analysis
Hanlong Zhu, Si Zhao, Ruonan Jiao, Jian Zhou, Chunmei Zhang, Lin Miao
Journal of Gastroenterology and Hepatology.2020; 35(11): 1858. CrossRef - Laparoscopy‑assisted endoscopic full‑thickness resection of upper gastrointestinal subepithelial tumors: A single‑center early experience
Prasit Mahawongkajit, Pakkavuth Chanswangphuvana
Molecular and Clinical Oncology.2020;[Epub] CrossRef Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review
Peng Liu, Fengbo Tan, Heli Liu, Jie Ge, Sheng Liu, Tianxiang Lei, Xianhui Zhao
Cancer Management and Research.2020; Volume 12: 7681. CrossRef- Laparoscopic Transabdominal Dissection and Transection of the Distal Rectum Followed by Local Excision Through the Anus for Rectal Gastrointestinal Stromal Tumor
Shin Emoto, Takashi Akiyoshi, Koji Fukata, Toshiya Nagasaki, Yosuke Fukunaga
Diseases of the Colon & Rectum.2020; 63(11): e542. CrossRef - Laparoscopic resectional oesophago-gastroplasty: a novel technique for minimally invasive treatment of large high gastric lesser curve GIST involving gastroesophageal junction
Mang Yik Foo, Baldwin P M Yeung, Jeremy T H Tan
Journal of Surgical Case Reports.2020;[Epub] CrossRef - Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map
Chen Li, Ke-Lu Yang, Quan Wang, Jin-Hui Tian, Yang Li, Zhi-Dong Gao, Xiao-Dong Yang, Ying-Jiang Ye, Ke-Wei Jiang
World Journal of Gastroenterology.2020; 26(47): 7550. CrossRef - Application of NOTES combined with ESD for the treatment of an exogenous gastric stromal tumor: A case report and review of the literature
Xiao-Bo Liu, Zi-Ye Gao, Sandeep Pandey, Bao-Zhen Shan, Ping Liu, Chuan-Tao Sun, Sheng-Bao Li, Shu Jin
World Academy of Sciences Journal.2020;[Epub] CrossRef - Laparoscopic versus open resection of gastrointestinal stromal tumors: survival outcomes from the NCDB
Colette S. Inaba, Austin Dosch, Christina Y. Koh, Sarath Sujatha-Bhaskar, Marija Pejcinovska, Brian R. Smith, Ninh T. Nguyen
Surgical Endoscopy.2019; 33(3): 923. CrossRef - Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method
Ming Liu, Liheng Liu, Erhu Jin
Gastric Cancer.2019; 22(4): 769. CrossRef - Per oral endoscopic tumor (POET) resection for treatment of upper gastrointestinal subepithelial tumors
Philip Wai Yan Chiu, Hon Chi Yip, Anthony Yuen Bun Teoh, Vivien Wai Yin Wong, Shannon Melissa Chan, Simon Kin Hung Wong, Enders Kwok Wai Ng
Surgical Endoscopy.2019; 33(4): 1326. CrossRef - Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang
Cancer Medicine.2019; 8(3): 1034. CrossRef - PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY
João Bernardo Sancio Rocha RODRIGUES, Renato Gomes CAMPANATI, Francisco NOLASCO, Athos Miranda BERNARDES, Soraya Rodrigues de Almeida SANCHES, Paulo Roberto SAVASSI-ROCHA
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2019;[Epub] CrossRef - Value of contrast‐enhanced harmonic endoscopic ultrasonography in differentiating between gastrointestinal stromal tumors: A meta‐analysis
Jia Yue Tang, Ke Gong Tao, Li Yuan Zhang, Kai Ming Wu, Jian Shi, Xin Zeng, Yong Lin
Journal of Digestive Diseases.2019; 20(3): 127. CrossRef - Future of full thickness resection – Devices, indications, robotics, what is missing
Philip WY Chiu
Techniques in Gastrointestinal Endoscopy.2019; 21(1): 48. CrossRef - Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs)
Mincong Wang, Anwei Xue, Wei Yuan, Xiaodong Gao, Min Fu, Yong Fang, Li Wang, Ping Shu, He Li, Yingyong Hou, Kuntang Shen, Yinghong Sun, Xinyu Qin
Journal of Gastrointestinal Surgery.2019; 23(11): 2136. CrossRef - Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors —8 cases: A case report
Jwa Hoon Kim, Min-Hee Ryu, Young Soo Park, Hyun Jin Kim, Hyojung Park, Yoon-Koo Kang
World Journal of Gastroenterology.2019; 25(16): 2010. CrossRef - Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion
Liangliang Xu, Ming Zhang, Mingqing Xu
Medicine.2019; 98(20): e15482. CrossRef - Endoscopic full-thickness resection for a gastrointestinal stromal tumor in a liver transplant recipient
Man Xie, Wei Rao, Peng Zhang, Qingxi Zhao, Zibin Tian
Medicine.2019; 98(31): e16669. CrossRef - Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients
Hanmei Chen, Jing Liu, Yuhong Zhou, Yingyong Hou, Guo Ma, Weimin Cai
Therapeutic Drug Monitoring.2019; 41(5): 582. CrossRef - Value of CT-Based Texture Analysis in Preoperative Prediction of the Grade of Gastrointestinal Stromal Tumors Compared to Conventional CT Imaging
Caiyue Ren, Shengping Wang, Shengjian Zhang, Zhaoxia Jiang
Iranian Journal of Radiology.2019;[Epub] CrossRef - Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
Fousséni Alassani, Boyodi Tchangai, Aklesso Bagny, Ablavi A. Adani-Ife, Kossigan A. Amavi, Tchin Darre, Komla Attipou
Oncology and Therapy.2019; 7(2): 159. CrossRef - Clinical Relevance of the Location of Gastric Gastrointestinal Stromal Tumors
Eun Jeong Gong
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2019; 19(3): 143. CrossRef - Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
Hyungwoo Cho, Min-Hee Ryu, Yongjune Lee, Young Soo Park, Ki-Hun Kim, Jwa Hoon Kim, Yangsoon Park, Sun Mi Lee, Chan Wook Kim, Beom Soo Kim, Moon-Won Yoo, Yoon-Koo Kang
The Oncologist.2019; 24(12): e1443. CrossRef - Gastrointestinal stromal tumors: Do we follow the current guidelines? A self-critique
MohammadEzzedien Rabie, Abdelelah Hummadi, Mohammad Bazeed, Ismail El Hakeem, AbdullaSaad Al Qahtani, Hesham Haroon, Abbas Al Zain
Saudi Surgical Journal.2019; 7(3): 100. CrossRef - Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
The Oncologist.2019; 24(11): e1212. CrossRef - The fourth space surgery: endoscopic subserosal dissection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer
Fei Liu, Song Zhang, Wei Ren, Tian Yang, Ying Lv, Tingsheng Ling, Xiaoping Zou, Lei Wang
Surgical Endoscopy.2018; 32(5): 2575. CrossRef - Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1. CrossRef - Subepitheliale Raumforderungen
N. Glaser, R. Thimme, A. Schmidt
Der Gastroenterologe.2018; 13(2): 113. CrossRef - Tyrosine kinase inhibitor therapies for gastrointestinal stromal tumours
Simone Mocellin, Sandro Pasquali, Luca Campana, Yuhong Yuan, Alessandro Gronchi, Ewen Griffiths, Ravinder Vohra
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef - Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib
Jianwei Tang, Rui Zhao, Xiaobo Zheng, Liangliang Xu, Yong Wang, Lei Feng, Shengsheng Ren, Peng Wang, Ming Zhang, Mingqing Xu
Medicine.2018; 97(29): e11400. CrossRef - A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
Journal of Gastrointestinal Surgery.2018; 22(12): 2150. CrossRef - Inhibition of stromal‐interacting molecule 1‐mediated store‐operated Ca2+ entry as a novel strategy for the treatment of acquired imatinib‐resistant gastrointestinal stromal tumors
Ziyi Yang, Lijia Pan, Shilei Liu, Fengnan Li, Wenjie Lv, Yijun Shu, Ping Dong
Cancer Science.2018; 109(9): 2792. CrossRef - Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe
Lin Tu, Peter Hohenberger, Heike Allgayer, Hui Cao
Visceral Medicine.2018; 34(5): 353. CrossRef - Gastric ectopic pancreas mimicking a gastrointestinal stromal tumour: A case report
Zdravko Štor, Jurij Hanžel
International Journal of Surgery Case Reports.2018; 53: 348. CrossRef - Tumor rupture of gastric gastrointestinal stromal tumors during endoscopic resection: a risk factor for peritoneal metastasis?
Shiyi Song, Wei Ren, Yi Wang, Shu Zhang, Song Zhang, Fei Liu, Qiang Cai, Guifang Xu, Xiaoping Zou, Lei Wang
Endoscopy International Open.2018; 06(08): E950. CrossRef - Drill needle aspiration biopsy for submucosal tumors in an experimental study
Masaya Uesato, Tomohide Tamachi, Naoyuki Hanari, Yorihiko Muto, Akiko Kagaya, Ryuma Urahama, Yukiko Ogura, Hiroshi Suito, Akira Nakano, Mizuho Aikawa, Takashi Oide, Hisahiro Matsubara
Gastric Cancer.2017; 20(3): 475. CrossRef - Tumor del estroma extragastrointestinal primario hepático gigante
Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
Cirugía Española.2017; 95(9): 547. CrossRef - Cancer biology of small gastrointestinal stromal tumors (<2 cm): What is the risk of malignancy?
K. Søreide
European Journal of Surgical Oncology (EJSO).2017; 43(7): 1344. CrossRef - An unexpected cause of gastric submucosal lesion
Rachid Guimarães Nagem
Einstein (São Paulo).2017; 15(1): 112. CrossRef - Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)
Mónica Ballesteros, Nadia Montero, Antonio López-Pousa, Gerard Urrútia, Ivan Solà, Gabriel Rada, Hector Pardo-Hernandez, Xavier Bonfill
BMC Medical Research Methodology.2017;[Epub] CrossRef - Laparoscopic management of gastric gastrointestinal stromal tumors: A retrospective 10-year single-center experience
Guan-Qun Liao, Tao Chen, Xiao-Long Qi, Yan-Feng Hu, Hao Liu, Jiang Yu, Guo-Xin Li
World Journal of Gastroenterology.2017; 23(19): 3522. CrossRef - Current research and treatment for gastrointestinal stromal tumors
Kheng Tian Lim, Kok Yang Tan
World Journal of Gastroenterology.2017; 23(27): 4856. CrossRef - Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16 Ink4A /p14 ARF gene expressions: An in vivo and in vitro study
Jiang-Li Wang, Jiang-Hong Wu, Cai Hong, Ya-Nong Wang, Ye Zhou, Zi-Wen Long, Ying Zhou, Hai-Shu Qin
Pathology - Research and Practice.2017; 213(12): 1542. CrossRef - Giant Primary Extra Gastrointestinal Stromal Tumor of the Liver
Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
Cirugía Española (English Edition).2017; 95(9): 547. CrossRef - Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
Rui Zhao, Yong Wang, Yuqian Huang, Yaping Cui, Lin Xia, Yi Chen, Wen Zhuang, Yong Zhou, Xiaoting Wu
Scientific Reports.2017;[Epub] CrossRef
- Clinical importance of tumor rupture in gastrointestinal stromal tumor
- 26,041 View
- 1,153 Download
- 149 Web of Science
- 133 Crossref
Original Article
- Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
- Daniel Keizman, Keren Rouvinov, Avishay Sella, Maya Gottfried, Natalie Maimon, Jenny J. Kim, Mario A. Eisenberger, Victoria Sinibaldi, Avivit Peer, Michael A. Carducci, Wilmosh Mermershtain, Raya Leibowitz-amit, Rony Weitzen, Raanan Berger
- Cancer Res Treat. 2016;48(1):281-287. Published online March 5, 2015
- DOI: https://doi.org/10.4143/crt.2014.289
-
Abstract
PDFPubReaderePub
- Purpose
Studies suggested the existence of a ‘trial effect', in which for a given treatment, participation in a clinical trial is associated with a better outcome. Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). We aimed to study the effect of clinical trial participation on the outcome of mRCC patients treated with sunitinib, which at present, is poorly defined.
Materials and Methods
The records of mRCC patients treated with sunitinib between 2004-2013 in 7 centers across 2 countries were reviewed. We compared the response rate (RR), progression free survival (PFS), and overall survival (OS), between clinical trial participants (n=49) and a matched cohort of non-participants (n=49) who received standard therapy. Each clinical trial participant was individually matched with a non participant by clinicopathologic factors. PFS and OS were determined by Cox regression.
Results
The groups were matched by age (median 64), gender (male 67%), Heng risk (favorable 25%, intermediate 59%, poor 16%), prior nephrectomy (92%), RCC histology (clear cell 86%), pre-treatment NLR (>3 in 55%, n=27), sunitinib induced hypertension (45%), and sunitinib dose reduction/treatment interruption (41%). In clinical trial participants versus non-participants, RR was partial response/stable disease 80% (n=39) versus 74% (n=36), and progressive disease 20% (n=10) versus 26% (n=13) (p=0.63, OR 1.2). The median PFS was 10 versus 11 months (HR=0.96, p=0.84), and the median OS 23 versus 24 months (HR=0.97, p=0.89).
Conclusions
In mRCC patients treated with sunitinib, the outcome of clinical trial participants was similar to that of non-participants who received standard therapy. -
Citations
Citations to this article as recorded by- Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer
Jae Joon Han, Jin Won Kim, Koung Jin Suh, Ji‐won Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun‐Wook Lee
Asia-Pacific Journal of Clinical Oncology.2019; 15(3): 158. CrossRef - Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study
Shinji Ohno, Hirofumi Mukai, Kazutaka Narui, Yasuo Hozumi, Yasuo Miyoshi, Hiroshi Yoshino, Hiroyoshi Doihara, Akihiko Suto, Motoshi Tamura, Takashi Morimoto, Hisamitsu Zaha, Takashi Chishima, Reiki Nishimura, Takashi Ishikawa, Yukari Uemura, Yasuo Ohashi
Breast Cancer Research and Treatment.2019; 176(3): 631. CrossRef - Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma
Anna M Czarnecka, Paweł Sobczuk, Jan Korniluk, Marta Spychalska, Krzysztof Bogusz, Anna Owczarek, Anna Brodziak, Dominika Labochka, Barbara Moszczuk, Cezary Szczylik
Future Oncology.2017; 13(1): 31. CrossRef - Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
Acta Oncologica.2017; 56(4): 582. CrossRef - Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region
Carsten Nieder, Mohsan A. Syed, Astrid Dalhaug, Adam Pawinski, Jan Norum
Medical Oncology.2017;[Epub] CrossRef - Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome
Agnieszka Rybarczyk, Jakub Klacz, Agata Wronska, Marcin Matuszewski, Zbigniew Kmiec, Piotr M. Wierzbicki
Oncology Reports.2017; 38(1): 427. CrossRef
- Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer
- 11,269 View
- 63 Download
- 8 Web of Science
- 6 Crossref
Case Report
- Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
- Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee
- Cancer Res Treat. 2013;45(4):349-353. Published online December 31, 2013
- DOI: https://doi.org/10.4143/crt.2013.45.4.349
-
Abstract
PDFPubReaderePub
- Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
-
Citations
Citations to this article as recorded by- The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani
Cancers.2022; 14(21): 5352. CrossRef - Hereditary renal cell tumors: Clinicopathologic importance
Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro
annals of urologic oncology.2021;[Epub] CrossRef Von Hippel-Lindau Disease: Current Challenges and Future Prospects
Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
OncoTargets and Therapy.2020; Volume 13: 5669. CrossRef- The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
Frontiers in Endocrinology.2020;[Epub] CrossRef - Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
European Urology.2019; 76(6): 754. CrossRef - The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
Frontiers in Oncology.2019;[Epub] CrossRef - A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
Cancer Biology & Therapy.2018; 19(9): 766. CrossRef - Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
Brian Shuch, Jin Zhang
Journal of Clinical Oncology.2018; 36(36): 3560. CrossRef - A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Research and Treatment.2016; 48(1): 409. CrossRef - Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
Internal Medicine.2016; 55(6): 629. CrossRef - Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
Oncotarget.2016; 7(51): 85306. CrossRef - Pharmacogenomic biomarkers for personalized cancer treatment
C. Rodríguez‐Antona, M. Taron
Journal of Internal Medicine.2015; 277(2): 201. CrossRef - Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
Journal of Clinical Investigation.2015; 125(5): 1987. CrossRef - Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
EPMA Journal.2015;[Epub] CrossRef
- The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
- 12,076 View
- 70 Download
- 15 Web of Science
- 14 Crossref
Review Article
- Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
- Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
- Cancer Res Treat. 2012;44(2):85-96. Published online June 30, 2012
- DOI: https://doi.org/10.4143/crt.2012.44.2.85
-
Abstract
PDFPubReaderePub
- Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.
-
Citations
Citations to this article as recorded by- Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
Journal of Gastrointestinal Cancer.2023; 54(1): 316. CrossRef - The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video)
Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li, Alessandro Granito
Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1. CrossRef - Gastrointestinal stromal tumor of the small intestine of high malignant potential
Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
PONS - medicinski casopis.2022; 19(1): 33. CrossRef - Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors
Joonhong Park, Hae Jung Sul, Jeong Goo Kim
Medicina.2021; 57(2): 174. CrossRef - The Pathologic Confirmation in Subepithelial Tumors
Kwan Hong Lee, Chan Kyoo Yoo, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, Oh Young Lee, Dong Soo Han, Byung Chul Yoon, Ho Soon Choi, Jai Hoon Yoon
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 215. CrossRef - Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
Haojie Du, Longgui Ning, Sha Li, Xinhe Lou, Hongtan Chen, Fengling Hu, Guodong Shan, Fenming Zhang, Guoqiang Xu
Clinical and Translational Gastroenterology.2020; 11(3): e00156. CrossRef - Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schӧffski
British Journal of Cancer.2020; 122(8): 1158. CrossRef - Life-threatening bleeding with intussusception due to gastrointestinal stromal tumor: a case report
Min Sung Kim, In Teak Woo, Young Min Jo, Jin Hyung Lee, Byung Sam Park
Surgical Case Reports.2019;[Epub] CrossRef - Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: Single center experience
Cristina Maggioni, Atsuo Shida, Raffaello Mancini, Luigi Ioni, Graziano Pernazza
The International Journal of Medical Robotics and Computer Assisted Surgery.2019;[Epub] CrossRef - A novel technique for removing large gastric subepithelial tumors with ESD method in the subcardia region
Bingtuan Liu, Han Chen, Weifeng Zhang, Guoxin Zhang
Oncology Letters.2019;[Epub] CrossRef - Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors
In Sun Yoon, Ji Hoon Shin, Kichang Han, Pyo Nyun Kim, Ki Hun Kim, Yoon-Koo Kang, Heung Kyu Ko
Korean Journal of Radiology.2018; 19(1): 54. CrossRef - Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1. CrossRef - A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
Journal of Gastrointestinal Surgery.2018; 22(12): 2150. CrossRef - Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Toni
Therapeutic Advances in Medical Oncology.2018;[Epub] CrossRef - Current research and treatment for gastrointestinal stromal tumors
Kheng Tian Lim, Kok Yang Tan
World Journal of Gastroenterology.2017; 23(27): 4856. CrossRef - Extra-gastrointestinal stromal tumor of the pancreas: report of a case
Hyung Jun Kwon
Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(4): 237. CrossRef - The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
Toshirou Nishida, Jean-Yves Blay, Seiichi Hirota, Yuko Kitagawa, Yoon-Koo Kang
Gastric Cancer.2016; 19(1): 3. CrossRef - Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
Cancer Research and Treatment.2016; 48(1): 162. CrossRef - Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
Cancer Research and Treatment.2016; 48(2): 546. CrossRef - Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)
Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, Baek-Yeol Ryoo, George D. Demetri, Yoon-Koo Kang
European Journal of Cancer.2016; 52: 201. CrossRef - Schwannoma of the stomach: a case report
Aminder Singh, Ankur Mittal, Bhavna Garg, Neena Sood
Journal of Medical Case Reports.2016;[Epub] CrossRef - Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Research and Treatment.2016; 48(4): 1155. CrossRef - Unusual gastroduodenal intussusception secondary to a gastrointestinal stromal tumor of the gastric fundus
Toshihide Komatsubara, Toru Zuiki, Alan Kawarai Lefor, Norio Hirota, Jun Oki
International Journal of Surgery Open.2016; 5: 33. CrossRef - Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial
Changhoon Yoo, Yoon-Koo Kang
Clinical Investigation.2015; 5(7): 665. CrossRef - The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
Seong Joon Park, Min-Hee Ryu, Baek-Yeol Ryoo, Young Soo Park, Byeong Seok Sohn, Hwa Jung Kim, Chan Wook Kim, Ki-Hun Kim, Chang Sik Yu, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang
Annals of Surgical Oncology.2014; 21(13): 4211. CrossRef - Minimally invasive surgery for submucosal (subepithelial) tumors of the stomach
Chang Min Lee
World Journal of Gastroenterology.2014; 20(36): 13035. CrossRef - Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu, M-H Ryu
British Journal of Cancer.2013; 109(9): 2309. CrossRef - Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri
The Lancet Oncology.2013; 14(12): 1175. CrossRef - Surgeon's role for gastric gastrointestinal stromal tumor in imatinib era
Ji Yeon Park, Young-Woo Kim
Korean Journal of Clinical Oncology.2013; 9(1): 5. CrossRef - Diagnosis and Treatment of Gastrointestinal Stromal Tumor
Yoon-Koo Kang, Dong Hoe Koo
Korean Journal of Medicine.2013; 85(4): 341. CrossRef - Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
Seong-Ho Kong, Han-Kwang Yang
Journal of Gastric Cancer.2013; 13(1): 3. CrossRef - Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen
World Journal of Surgical Oncology.2012;[Epub] CrossRef
- Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
- 51,306 View
- 133 Download
- 32 Crossref
Case Report
- Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
- Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
- Cancer Res Treat. 2010;42(3):180-184. Published online September 30, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.3.180
-
Abstract
PDFPubReaderePub
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
-
Citations
Citations to this article as recorded by- Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
Elodie Klajer, Louis Garnier, Morgan Goujon, Friederike Schlurmann-Constans, Benoite Mery, Thierry Nguyen Tan Hon, Guillaume Mouillet, Fabien Calcagno, Antoine Thiery-Vuillemin
Seminars in Oncology.2020; 47(2-3): 103. CrossRef - Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini, Camillo Porta
EMJ Nephrology.2016; : 66. CrossRef - Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro
Current Urology Reports.2015;[Epub] CrossRef - Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of Experience
Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk, Cezary Szczylik
Future Oncology.2015; 11(16): 2267. CrossRef - Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong-Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha
European Journal of Cancer.2014; 50(4): 746. CrossRef - Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef - A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte, Pierre I. Karakiewicz
Cancer Treatment Reviews.2013; 39(4): 388. CrossRef - Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moscetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cin
BJU International.2012; 110(5): 692. CrossRef
- Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
- 10,172 View
- 67 Download
- 8 Crossref
Original Article
- Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
- Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
- Cancer Res Treat. 2009;41(2):67-72. Published online June 30, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.2.67
-
Abstract
PDFPubReaderePub
Purpose The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
Materials and Methods Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.
Results Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).
Conclusion Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
-
Citations
Citations to this article as recorded by- pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
Ling Wang, Fangqing Cai, Yixuan Li, Xiaolan Lin, Yuting Wang, Weijie Liang, Caiyu Liu, Cunze Wang, Junshan Ruan
International Journal of Nanomedicine.2024; Volume 19: 9821. CrossRef - Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
Kidney Cancer.2022; 6(1): 37. CrossRef - High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim
Cancers.2022; 14(23): 5985. CrossRef - Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma
Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park
Medicine.2021; 100(31): e26826. CrossRef - Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi
JCO Global Oncology.2020; (6): 19. CrossRef - Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik
Cancer Science.2020; 111(3): 907. CrossRef - First-Line Axitinib Versus Sorafenib in Asian Patients with Metastatic Renal Cell Carcinoma: Exploratory Subgroup Analyses of Phase III Data
Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo
Future Oncology.2019; 15(1): 53. CrossRef - The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
Oncology and Therapy.2019; 7(1): 1. CrossRef - Risk of fatal adverse events in cancer patients treated with sunitinib
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2019; 137: 115. CrossRef - Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef - Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
BioMed Research International.2018; 2018: 1. CrossRef - Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma
Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad
Journal of Cancer Research and Therapeutics.2018; 14(6): 1303. CrossRef - Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
Acta Oncologica.2017; 56(4): 582. CrossRef - Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma
Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai
Molecular Medicine Reports.2017; 16(4): 5023. CrossRef - miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma
Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai
Molecular Medicine Reports.2017;[Epub] CrossRef - Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef - BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
Cancer Chemotherapy and Pharmacology.2016; 78(3): 623. CrossRef - Key predictive factors for efficacy of axitinib in first-line
metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a
randomized, double-blind phase II study
Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Japanese Journal of Clinical Oncology.2016; 46(11): 1031. CrossRef - Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu
PLOS ONE.2016; 11(2): e0148177. CrossRef - Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
M Darrad, R Wilson
Journal of Clinical Urology.2016; 9(1): 32. CrossRef - Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn
International braz j urol.2016; 42(4): 694. CrossRef - Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI
Molecular Medicine Reports.2016; 13(6): 5386. CrossRef - Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan
Clinical Genitourinary Cancer.2015; 13(4): e285. CrossRef - Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday
Pathology & Oncology Research.2015; 21(3): 775. CrossRef - Axitinib plasma pharmacokinetics and ethnic differences
Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala
Investigational New Drugs.2015; 33(2): 521. CrossRef - Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
Tomohiro Terada, Satoshi Noda, Ken-ichi Inui
Pharmacology & Therapeutics.2015; 152: 125. CrossRef - RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn
Annals of Oncology.2015; 26(11): 2300. CrossRef - Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
Cancer Science.2015; 106(12): 1714. CrossRef - Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
Wael Abdelgawad Edesa, Raafat Ragaey Abdelmalek
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971. CrossRef - Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells
NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA
Oncology Reports.2015; 34(2): 1058. CrossRef - Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng
British Journal of Cancer.2014; 110(6): 1433. CrossRef - The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara
Therapeutic Drug Monitoring.2014; 36(3): 310. CrossRef - Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef - Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh
Cancer Medicine.2014; 3(6): 1517. CrossRef - Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS
International Journal of Oncology.2014; 44(1): 5. CrossRef - Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore
British Journal of Cancer.2013; 108(12): 2470. CrossRef - Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez
Cancer Treatment Reviews.2013; 39(3): 230. CrossRef - Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 825. CrossRef - Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Annals of Surgical Oncology.2013; 20(13): 4397. CrossRef - Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 853. CrossRef - Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt
Expert Opinion on Drug Safety.2013; 12(4): 455. CrossRef - Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang
Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043. CrossRef - Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients
노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화
Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210. CrossRef - Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura
Drug Metabolism and Disposition.2013; 41(8): 1592. CrossRef - Famitinib in metastatic renal cell carcinoma: a single center study
Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG
Chinese Medical Journal.2013; 126(22): 4277. CrossRef - Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
Aiping ZHOU
Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132. CrossRef - Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
Investigational New Drugs.2012; 30(2): 819. CrossRef - Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho, Jinsoo Chung
Korean Journal of Urology.2012; 53(4): 217. CrossRef - Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura
Drug Metabolism and Pharmacokinetics.2012; 27(6): 631. CrossRef - Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek
Japanese Journal of Clinical Oncology.2011; 41(12): 1380. CrossRef - Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
European Journal of Cancer.2011; 47(17): 2592. CrossRef - Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim
Korean Journal of Urology.2010; 51(7): 450. CrossRef - Kidney Cancer Working Group Report
S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid
Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51. CrossRef - Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer
Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis
Thyroid.2010; 20(6): 597. CrossRef - The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn
Japanese Journal of Clinical Oncology.2010; 40(10): 980. CrossRef - Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
Cancer Research and Treatment.2010; 42(3): 180. CrossRef - Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo
Korean Journal of Urology.2010; 51(6): 379. CrossRef
- pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
- 12,719 View
- 74 Download
- 57 Crossref
Case Report
- TTP-HUS Associated with Sunitinib
- Moon Ki Choi, Jung Yong Hong, Jun Ho Jang, Ho Yeong Lim
- Cancer Res Treat. 2008;40(4):211-213. Published online December 31, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.4.211
-
Abstract
PDFPubReaderePub
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Adverse reactions to drugs increasingly are reported as probable causes of TTP-HUS. Many chemotherapeutic agents have also been implicated in causing TTP-HUS. We reported a woman with metastatic renal cell carcinoma who presented with TTP-HUS associated with sunitinib. She had gross hematuria and generalized edema. The hemoglobin concentration was 8.9 g/dl and the platelet count was 46,000/mm3. Her reticulocyte count was increased to 4.1% and the peripheral blood smear revealed red blood cell fragmentation and spherocytes. The patient completely recovered after discontinuing the use of sunitinib and undergoing plasmapheresis. Because of the increasing use of sunitinib in the treatment of cancer patients, oncologists should be aware of the possibility of TTP-HUS related to sunitinib, as early recognition and prompt therapeutic intervention can be beneficial.
-
Citations
Citations to this article as recorded by- Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
Anukul Ghimire, Rebecca Brassington, Kim Solez, Aminu Bello
BMJ Case Reports.2024; 17(1): e255841. CrossRef - Nonthrombocytopenic, noninflammatory simplex purpura during sunitinib therapy
Marta García‐Legaz Martínez, Álvaro Martínez‐Doménech, Gemma Pérez‐Pastor, Jorge Magdaleno‐Tapial, Cristian Valenzuela‐Oñate, Víctor Alegre‐de Miquel, Amparo Pérez‐Ferriols
International Journal of Dermatology.2019;[Epub] CrossRef - Thrombotic microangiopathy in cancer patients
Alexander D. Makatsariya, Ismail Elalamy, Alexander V. Vorobev, Angelina S. Bakhtina, Muyang Meng, Victoria O. Bitsadze, Jamilya Kh. Khizroeva
Annals of the Russian academy of medical sciences.2019; 74(5): 323. CrossRef - Thrombotic microangiopathy in cancer
Ilene Ceil Weitz
Thrombosis Research.2018; 164: S103. CrossRef - Cancer drugs and the glomerulus
Hitesh H Shah, Nupur N Uppal, Mark A Perazella
Journal of Onco-Nephrology.2018; 2(2-3): 78. CrossRef - Therapeutic Plasma Exchange and Its Impact on Drug Levels
Caleb W Cheng, Jeanne E Hendrickson, Christopher A Tormey, Davinder Sidhu
American Journal of Clinical Pathology.2017; 148(3): 190. CrossRef - Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Hassan Izzedine, Mark A. Perazella
American Journal of Kidney Diseases.2015; 66(5): 857. CrossRef - Sunitinib-associated Thrombotic Microangiopathy: A Significant Risk
F.D. Buckley, G. Preston, D.J. Meiklejohn, D. Adamson
Clinical Oncology.2014; 26(8): 515. CrossRef - Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature
Rebecca L. Ruebner, Lawrence Copelovitch, Nicholas F. Evageliou, Michelle R. Denburg, Jean B. Belasco, Bernard S. Kaplan
Pediatric Nephrology.2014; 29(5): 863. CrossRef - Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
Liliane Hobeika, Sally E Self, Juan Carlos Q Velez
BMC Nephrology.2014;[Epub] CrossRef - Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
Imane El Dika, Deborah Mukherji, Sally Temraz, Rita Assi, Ali Shamseddine
Case Reports in Medicine.2014; 2014: 1. CrossRef - Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor
Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Nilgün Kaya
Journal of Oncology Pharmacy Practice.2014; 20(4): 298. CrossRef - A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura
Eun Jin Kim, Yun Mi Choi, Sin Won Lee, Yeon Jung Ha, Jae Lyun Lee
Korean Journal of Medicine.2013; 84(2): 303. CrossRef - Thrombotic Microangiopathy Associated with Bortezomib Treatment in a Patient with Relapsed Multiple Myeloma
Urpu Salmenniemi, Kari Remes
Hematology Reports.2012; 4(2): e13. CrossRef - Hematologic toxicities of small molecule tyrosine kinase inhibitors
Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari
Targeted Oncology.2011; 6(4): 203. CrossRef - Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
H. Izzedine, C. Massard, J. C. Soria
Clinical Kidney Journal.2011; 4(1): 78. CrossRef - Docetaxel-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome–Related Complex in a Patient With Metastatic Prostate Cancer?
Anuj Shrestha, Pam Khosla, Yunfei Wei
American Journal of Therapeutics.2011; 18(5): e167. CrossRef - Micafungin-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Review of the Literature
Maisa Nazzal, Fadi Safi, Freda Arma, Mustafa Nazzal, Mahvish Muzaffar, Ragheb Assaly
American Journal of Therapeutics.2011; 18(6): e258. CrossRef - Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2009; 41(2): 67. CrossRef
- Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
- 10,562 View
- 65 Download
- 19 Crossref
First
Prev
